Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Lee E, Burgess K · Alternative Therapies in Health and Medicine

No biomarker changes or adverse effects in two people over two days — the entire published human safety dataset for systemic BPC-157.

Population

Two healthy adults

Intervention

IV BPC-157 10 mg then 20 mg on consecutive days

Comparator

None

Limitations

n=2, 48-hour horizon, no control, low-rigor journal; says nothing about longer-term or repeated dosing.